https://www.trialnet.org/our-research/prevention-studies/hydroxychloroquine-hcq
Due to COVID-19, Hydroxychlorquine enrollment and trial procedures have changed. Click here for up to date information on Hydroxychlorquine enrollment and participant details.
Hydroxychloroquine (HCQ) is approved by the Food and Drug Administration (FDA) and has been used for more than 60 years. It is used to treat other autoimmune diseases, including rheumatoid arthritis and lupus. HCQ has a good safety profile and is approved for use in children.
As with any medical intervention, there are risks and benefits to participating in this study. Before you decide to participate, a member our research team will explain all potential risks and benefits, and answer any questions you may have.
Who Can Participate
To find out if this study is right for you, the first step is to sign up for Pathway to Prevention screening. To participate in the HCQ Prevention Study, you need to:
be at least 3 years old
have two or more diabetes-related autoantibodies (confirmed by TrialNet screening in last 6 months)
have normal results on an oral glucose tolerance test (OGTT) within 7 weeks of starting the study
be able to swallow a whole capsule
NOT be pregnant or planning to become pregnant while in the study
NOT have any medical conditions that might make it unsafe for you to be in this study